文献速递生殖医学

男性成年及儿童期癌症幸存者通过辅助生殖技术实现父权:一项全国性登记研究

Paternity through use of assisted reproduction technology in male adult and childhood cancer survivors: a nationwide register study.
PubMed 文献 · Hum Reprod · 2023-01-01

这项基于瑞典医学出生登记库的全国性人群研究纳入1994至2014年间首次生育的1 159 959名男性,比较有癌症史者与无癌症史者使用IVF/ICSI实现父权的 likelihood。有癌症史的父亲使用辅助生殖技术更频繁,尤其是睾丸癌、前列腺癌及血液淋巴系统恶性肿瘤幸存者,且以ICSI治疗为主。

要点

  • 儿童期癌症幸存者仅ICSI使用增加(aOR 3.52,95%CI 2.52-4.93),IVF无显著差异。
  • 青少年及年轻成人癌症幸存者ICSI使用增加(aOR 6.84,95%CI 5.64-8.30),IVF无显著差异。
  • 成年癌症幸存者ICSI(aOR 5.52)和IVF(aOR 1.32)使用均增加。

核心结论

  • 有癌症史的 fathers 使用辅助生殖技术(尤其ICSI)实现父权更频繁,主要见于睾丸癌、前列腺癌及血液淋巴系统恶性肿瘤幸存者。

研究设计与样本

  • 基于瑞典医学出生登记库的全国性人群研究,纳入1994至2014年间在瑞典首次生育的1 159 959名男性,其中有癌症史者5372名,无癌症诊断对照1 154 587名。
  • 通过个人识别号链接瑞典辅助生殖质量登记库、瑞典癌症登记库、瑞典多代登记库和瑞典教育登记库数据。
  • 采用logistic回归模型评估IVF/ICSI使用与癌症史的关联,校正父亲教育程度、生育时年龄和受孕年份,报告粗比值比和校正比值比(aOR)及95%CI。

主要发现

  • 儿童期癌症幸存者仅ICSI使用增加(aOR 3.52,95%CI 2.52-4.93;P < 0.001),IVF无显著差异(aOR 1.02,95%CI 0.61-1.70;P = 0.955)。
  • 青少年及年轻成人癌症幸存者ICSI使用增加(aOR 6.84,95%CI 5.64-8.30;P < 0.001),IVF无显著差异(aOR 1.27,95%CI 0.90-1.80;P = 0.17)。
  • 成年癌症幸存者ICSI(aOR 5.52,95%CI 4.86-6.27;P < 0.001)和IVF(aOR 1.32,95%CI 1.09-1.60;P = 0.004)使用均增加。
  • 亚组分析中,儿童期睾丸癌(aOR 5.15,95%CI 1.20-22.0)、软组织及骨癌(aOR 4.70,95%CI 2.13-10.4)、血液淋巴系统癌(aOR 4.49,95%CI 2.72-7.40)、中枢神经系统及眼癌(aOR 2.64,95%CI 1.23-5.67)幸存者ICSI使用增加。
  • 青少年及年轻成人睾丸癌(aOR 15.4,95%CI 11.5-20.7)、血液淋巴系统癌(aOR 9.84,95%CI 6.93-14.0)、软组织及骨癌(aOR 6.83,95%CI 3.53-13.2)幸存者ICSI使用增加;成年前列腺癌(aOR 15.7,95%CI 6.70-36.9)、睾丸癌(aOR 9.54,95%CI 7.81-11.7)、血液淋巴系统癌(aOR 11.3,95%CI 8.63-14.9)、消化呼吸泌尿生殖道癌(aOR 2.62,95%CI 1.75-3.92)、中枢神经系统及眼癌(aOR 2.74,95%CI 1.48-5.08)、皮肤癌(aOR 1.68,95%CI 1.08-2.62)幸存者ICSI使用增加。

临床怎么用

  • 作者认为,研究结果凸显了哪些男性癌症幸存者群体可从生育力护理中获益,从而改善未来的生育治疗政策。

局限性

  • 无法获取未能生育子女的男性信息,因此结果不能估计有癌症史男性的不孕风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How does a history of cancer affect the likelihood of using assisted reproduction in order to achieve paternity? SUMMARY ANSWER: As compared to men with no history of cancer, use of assisted reproduction to achieve paternity was more frequent in fathers with a history of cancer, mainly those with testicular, prostate, and hematological and lymphatic malignancies. WHAT IS KNOWN ALREADY: Although it is well known that different types of cancer and their treatment may have a negative impact on fertility, there is a lack of data regarding the use of IVF and ICSI among male cancer survivors. STUDY DESIGN, SIZE, DURATION: In this population-based nation-wide study using the Swedish Medical Birth Register, we identified all men who fathered their first-born child in Sweden between 1994 and 2014. Using personal identification numbers, anonymized data from the Swedish National Quality of Assisted Reproduction Register, Swedish Cancer Register, Swedish Multi-generation Register, and Swedish Education Register were linked with the Swedish Medical Birth Register. PARTICIPANTS/MATERIALS, SETTING, METHODS: During the study period, a total of 1 181 488 men fathering their first-born child were identified. Of these, 26 901 fathers had a cancer diagnosis. Fathers diagnosed with cancer with <12 months from offspring conception, or with a cancer diagnosis after offspring conception, were excluded (n = 21 529). The remaining fathers who had a history of cancer (n = 5372) were divided into three groups based on age at cancer diagnosis (<15, ≥15 and <24, or ≥24 years). For subgroup analyses, they were also grouped according to the cancer location using ICD-7 codes. The fathers with no cancer diagnosis (n = 1 154 587), were included as controls. In total, 1 159 959 men were included. Associations between IVF/ICSI use and history of cancer were evaluated using logistic regression models, unadjusted and adjusted for paternal education, fathers age at childbirth, and year of conception, yielding crude and adjusted odds ratio (aOR), respectively, with a 95% CI. MAIN RESULTS AND THE ROLE OF CHANCE: As compared to controls, childhood cancer survivors were only more likely to achieve paternity through ICSI (aOR 3.52, 95% CI 2.52-4.93; P < 0.001) but not through IVF treatment (aOR 1.02, 95% CI 0.61-1.70; P = 0.955). Similarly, teenage and young adult cancer survivors were more likely to father through ICSI treatment (aOR 6.84, 95% CI 5.64-8.30; P < 0.001) but not using IVF (aOR 1.27, 95% CI 0.90-1.80; P = 0.17). However, adult cancer survivors were more likely to conceive through either ICSI (aOR 5.52, 95% CI 4.86-6.27; P < 0.001) or IVF treatment (aOR 1.32, 95% CI 1.09-1.60; P = 0.004). In subgroup analyses, childhood survivors of testicular cancer (aOR 5.15, 95% CI 1.20-22.0; P = 0.027), soft tissue and bone cancers (aOR 4.70, 2.13-10.4; P < 0.001), hematological and lymphatic cancers (aOR 4.49, 95% CI 2.72-7.40; P < 0.001), or central nervous system (CNS) and eye cancers (aOR 2.64, 95% CI 1.23-5.67; P = 0.012), were at an increased likelihood of fathering through ICSI. Teenage and young adult survivors of testicular cancer (aOR 15.4, 95% CI 11.5-20.7; P < 0.001), hematological and lymphatic cancers (aOR 9.84, 95% CI 6.93-14.0; P < 0.001), or soft tissue and bone cancers (aOR 6.83, 95% CI 3.53-13.2; P < 0.001) were more likely to father through ICSI treatment. Adult survivors of prostate cancer (aOR 15.7, 95% CI 6.70-36.9; P < 0.001), testicular cancer (aOR 9.54, 95% CI 7.81-11.7; P < 0.001), hematological and lymphatic cancers (aOR 11.3, 95% CI 8.63-14.9; P < 0.001), digestive, respiratory, and urogenital tract cancers (aOR 2.62, 95% CI 1.75-3.92; P < 0.001), CNS and eye cancers (aOR 2.74, 95% CI 1.48-5.08; P = 0.001), or skin cancer (aOR 1.68, 95% CI 1.08-2.62; P = 0.022) were more likely to father through ICSI treatment. Only teenage and young adult survivors of hematological and lymphatic cancers (aOR 1.98, 95% CI 1.10-3.56; P = 0.022) and adult survivors of testicular cancer (aOR 1.88, 95% CI 1.37-2.58; P < 0.001) were significantly more likely to achieve fatherhood using IVF treatment. LIMITATIONS, REASONS FOR CAUTION: Information on men failing to father children was not available, and thus our results cannot estimate the risk of infertility in men with a history of cancer. WIDER IMPLICATIONS OF THE FINDINGS: Use of ART, in particular ICSI, was significantly more frequent in fathers with malignancies of the male reproductive tract or hematological and lymphatic systems. Our findings highlight which groups of male cancer survivors would benefit from access to fertility care, thereby improving future fertility treatment policies. STUDY FUNDING/COMPETING INTEREST(S): The study received funding from the Swedish Cancer Society, Swedish Childhood Cancer Society, and the Swedish Government Fund for Clinical Research. There are no competing interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kitlinski M, Giwercman A, Elenkov A, et al. Paternity through use of assisted reproduction technology in male adult and childhood cancer survivors: a nationwide register study. Hum Reprod. 2023. PMID: 36773319. doi:10.1093/humrep/dead026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。